
Loyola University Medical Center is offering a treatment called LDL apheresis, which is similar to kidney dialysis.
This treatment is for patients who have been unable to control cholesterol with lifestyle changes and medications.
Advertisement
Once every two weeks, a patient spends two to four hours connected to an apheresis unit that removes 70-to-80 percent of the patient's LDL (bad) cholesterol, then returns the blood to the body. The good HDL cholesterol is not removed.
Loyola is among a handful of centers in the Midwest - and the only academic medical center in Chicago -- to offer LDL apheresis.
The Loyola LDL Apheresis Program include patients with coronary heart disease who have LDL cholesterol greater than 200 mg/dL, and patients without coronary artery disease who have LDL levels greater than 300 mg/dL.
About 1 in 500 people have genetic abnormalities that cause LDL cholesterol levels three to five times as high as normal levels. The condition, called familial hypercholesterolemia, causes heart disease at a young age.
Fran Tobias, 56, who lives in Glen Ellyn, is successfully controlling her LDL by coming for apheresis treatments at Loyola every two weeks.
Familial hypercholesterolemia runs in her family. Her father died of a heart attack in his early 40s, her mother had a heart attack at age 45, and two brothers died of heart disease. Tobias had her first heart attack at age 37, a second heart attack at age 45, a quintuple bypass surgery and eight stents.
"This is literally a lifesaver for me. If I were to stop, I probably would have another heart attack within 18 months to two years," Tobias said.
The Loyola LDL Apheresis Program is multidisciplinary. LDL apheresis is done under the guidance of medical specialists from Loyola's transfusion service, and patients have periodic clinical follow-ups with a lipidologist (cholesterol specialist).
The program is directed by Binh An P. Phan, MD, and Phillip J. DeChristopher, MD, PhD. Phan is director of Loyola's Preventive Cardiology Program and DeChristopher is director of Transfusion Medicine and the Apheresis Center.
"The aim of the Loyola LDL Apheresis Program is to provide a multidisciplinary specialized service for the comprehensive evaluation and treatment of patients who require LDL apheresis," Phan said.
Source: ANI
The Loyola LDL Apheresis Program include patients with coronary heart disease who have LDL cholesterol greater than 200 mg/dL, and patients without coronary artery disease who have LDL levels greater than 300 mg/dL.
Advertisement
About 1 in 500 people have genetic abnormalities that cause LDL cholesterol levels three to five times as high as normal levels. The condition, called familial hypercholesterolemia, causes heart disease at a young age.
Fran Tobias, 56, who lives in Glen Ellyn, is successfully controlling her LDL by coming for apheresis treatments at Loyola every two weeks.
Familial hypercholesterolemia runs in her family. Her father died of a heart attack in his early 40s, her mother had a heart attack at age 45, and two brothers died of heart disease. Tobias had her first heart attack at age 37, a second heart attack at age 45, a quintuple bypass surgery and eight stents.
"This is literally a lifesaver for me. If I were to stop, I probably would have another heart attack within 18 months to two years," Tobias said.
The Loyola LDL Apheresis Program is multidisciplinary. LDL apheresis is done under the guidance of medical specialists from Loyola's transfusion service, and patients have periodic clinical follow-ups with a lipidologist (cholesterol specialist).
The program is directed by Binh An P. Phan, MD, and Phillip J. DeChristopher, MD, PhD. Phan is director of Loyola's Preventive Cardiology Program and DeChristopher is director of Transfusion Medicine and the Apheresis Center.
"The aim of the Loyola LDL Apheresis Program is to provide a multidisciplinary specialized service for the comprehensive evaluation and treatment of patients who require LDL apheresis," Phan said.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest General Health News

The Pakistan Ministry has announced the commencement of a nationwide polio vaccination campaign beginning on October 2, aiming to immunize more children.

In a tragic incident, a woman in the US experienced the loss of all her limbs as a result of a bacterial outbreak linked to the consumption of contaminated fish.

FluMos-v2, a unique universal influenza vaccine candidate, undergoing a phase 1 trial at NIH, increases recipients' immunity against many influenza viruses.

In Pakistan, the polio campaign focuses on more than 270,000 children under the age of five years, residing in areas with insufficient vaccine coverage.

Dangers of Wrong Diagnosis: Diagnostic errors in healthcare can increase the risk of permanent disabilities and deaths.